High-resolution characterization of allelic and haplotypic HLA frequency distribution in a Spanish population using high-throughput next-generation sequencing.


Journal

Human immunology
ISSN: 1879-1166
Titre abrégé: Hum Immunol
Pays: United States
ID NLM: 8010936

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 10 07 2018
revised: 07 02 2019
accepted: 09 02 2019
pubmed: 15 2 2019
medline: 18 12 2019
entrez: 15 2 2019
Statut: ppublish

Résumé

Next-generation sequencing (NGS) at the HLA-A, -B, -C, -DPA1, -DPB1, -DQA1, -DQB1, -DRB1 and -DRB3/4/5 loci was performed on 282 healthy unrelated individuals from different major regions of Spain. High-resolution HLA genotypes defined by full sequencing of class I loci and extended coverage of class II loci were obtained to determine allele frequencies and also to estimate extended haplotype frequencies. HLA alleles were typed at the highest resolution level (4-field level, 4FL); with exception of a minor deviation in HLA-DPA1, no statistically significant deviations from expected Hardy Weinberg Equilibrium (HWE) proportions were observed for all other HLA loci. This study provides new 4FL-allele and -haplotype frequencies estimated for the first time in the Spanish population. Furthermore, our results describe extended haplotypes (including the less frequently typed HLA-DPA1 and HLA-DQA1 loci) and show distinctive haplotype associations found at 4FL-allele definition in this Spanish population study. The distinctive allelic and haplotypic diversity found at the 4FL reveals the high level of heterozygosity and specific haplotypic associations displayed that were not apparent at 2-field level (2FL). Overall, these results may contribute as a useful reference source for future population studies, for HLA-disease association studies as a healthy control group dataset and for improving donor recruitment strategies of bone marrow registries. HLA genotyping data of this Spanish population cohort was also included in the 17th International Histocompatibility and Immunogenetics Workshop (IHIW) as part of the study of HLA diversity in unrelated worldwide populations using NGS.

Identifiants

pubmed: 30763600
pii: S0198-8859(19)30150-8
doi: 10.1016/j.humimm.2019.02.005
pmc: PMC6599556
mid: NIHMS1523909
pii:
doi:

Substances chimiques

HLA Antigens 0
Histocompatibility Antigens Class I 0
Histocompatibility Antigens Class II 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

429-436

Subventions

Organisme : NINDS NIH HHS
ID : U19 NS095774
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Références

Tissue Antigens. 2001 Feb;57(2):138-43
pubmed: 11260508
Hum Immunol. 2001 Sep;62(9):910-21
pubmed: 11543893
Am J Hum Genet. 2002 Oct;71(4):759-76
pubmed: 12297984
Tissue Antigens. 2003 May;61(5):384-92
pubmed: 12753657
Tissue Antigens. 2004 Dec;64(6):687-95
pubmed: 15546342
Tissue Antigens. 2005 Aug;66(2):93-8
pubmed: 16029428
Tissue Antigens. 2007 Apr;69 Suppl 1:192-7
pubmed: 17445199
Hum Immunol. 2008 Jul;69(7):443-64
pubmed: 18638659
Am J Hum Genet. 2008 Dec;83(6):725-36
pubmed: 19061982
Tissue Antigens. 2010 Apr;75(4):291-455
pubmed: 20356336
Tissue Antigens. 2010 Dec;76(6):442-58
pubmed: 20860586
Hum Immunol. 2011 Feb;72(2):144-9
pubmed: 20974205
Tissue Antigens. 2011 Jan;77(1):45-53
pubmed: 21155721
Immunology. 2011 Jun;133(2):143-64
pubmed: 21480890
Mol Biol Rep. 2012 Feb;39(2):1387-94
pubmed: 21633894
Tissue Antigens. 2011 Oct;78(4):249-55
pubmed: 21929573
Philos Trans R Soc Lond B Biol Sci. 2012 Mar 19;367(1590):820-9
pubmed: 22312049
Immunogenetics. 2012 Aug;64(8):559-69
pubmed: 22526601
Proc Natl Acad Sci U S A. 2012 May 29;109(22):8676-81
pubmed: 22589303
Tissue Antigens. 2012 Oct;80(4):341-55
pubmed: 22994155
Int J Immunogenet. 2013 Feb;40(1):60-5
pubmed: 23198982
Hum Immunol. 2013 Mar;74(3):330-40
pubmed: 23200758
Hum Immunol. 2013 Mar;74(3):325-9
pubmed: 23246585
Tissue Antigens. 2013 Apr;81(4):194-203
pubmed: 23510415
Hum Immunol. 2013 Oct;74(10):1313-20
pubmed: 23806270
PLoS One. 2013 Sep 23;8(9):e74442
pubmed: 24086347
Mol Biol Evol. 2014 Jun;31(6):1622-4
pubmed: 24603277
J Immunol Res. 2014;2014:971818
pubmed: 25126587
Nucleic Acids Res. 2015 Jan;43(Database issue):D784-8
pubmed: 25414323
Hum Immunol. 2016 Apr;77(4):313-6
pubmed: 26763581
Hum Immunol. 2016 Nov;77(11):1016-1023
pubmed: 27060029
Haematologica. 2016 Jun;101(6):680-7
pubmed: 27252513
Hum Immunol. 2016 Oct;77(10):832-840
pubmed: 27377016
HLA. 2017 Feb;89(2):104-113
pubmed: 28102034
BMC Bioinformatics. 2017 May 30;18(1):284
pubmed: 28558647
Hum Immunol. 2018 Jan;79(1):1-2
pubmed: 29122684
Hum Immunol. 2018 Feb;79(2):77-86
pubmed: 29247682
HLA. 2018 Mar;91(3):175-186
pubmed: 29327506
HLA. 2018 May 17;:null
pubmed: 29770608
G3 (Bethesda). 2018 Jul 31;8(8):2805-2815
pubmed: 29950428
Hum Immunol. 2019 Jan;80(1):62-66
pubmed: 30395911
Mol Biol Evol. 1987 Jul;4(4):406-25
pubmed: 3447015
J Mol Evol. 1983;19(2):153-70
pubmed: 6571220
Tissue Antigens. 1995 Apr;45(4):237-45
pubmed: 7638859

Auteurs

Gonzalo Montero-Martín (G)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: gmonter2@stanford.edu.

Kalyan C Mallempati (KC)

Stanford Blood Center, Stanford University School of Medicine, Palo Alto, CA, USA.

Sridevi Gangavarapu (S)

Stanford Blood Center, Stanford University School of Medicine, Palo Alto, CA, USA.

Francisco Sánchez-Gordo (F)

Histocompatibility, Centro de Transfusión de Málaga, Málaga, Spain.

Maria J Herrero-Mata (MJ)

Histocompatibility and Immunogenetics, Banc de Sang i Teixits, Barcelona, Spain.

Antonio Balas (A)

Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain.

Jose L Vicario (JL)

Histocompatibility, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain.

Florentino Sánchez-García (F)

Immunology, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain.

Maria F González-Escribano (MF)

Immunology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Manuel Muro (M)

Immunology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Maria R Moya-Quiles (MR)

Immunology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.

Rafael González-Fernández (R)

Immunology, Hospital Universitario Reina Sofía, Córdoba, Spain.

Javier G Ocejo-Vinyals (JG)

Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Luis Marín (L)

Molecular Biology-Hematology, Hospital Clínico Universitario, Salamanca, Spain.

Lisa E Creary (LE)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.

Kazutoyo Osoegawa (K)

Stanford Blood Center, Stanford University School of Medicine, Palo Alto, CA, USA.

Tamara Vayntrub (T)

Stanford Blood Center, Stanford University School of Medicine, Palo Alto, CA, USA.

Jose L Caro-Oleas (JL)

Histocompatibility and Immunogenetics, Banc de Sang i Teixits, Barcelona, Spain.

Carlos Vilches (C)

Immunogenetics and Histocompatibility, Instituto de Investigación Sanitaria Puerta de Hierro, Madrid, Spain.

Dolores Planelles (D)

Histocompatibility, Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain.

Marcelo A Fernández-Viña (MA)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH